Safety and efficacy of orlistat (Xenical; Roche) in African American and Caucasian children and adolescents with obesity-related comorbid conditions.

Trial Profile

Safety and efficacy of orlistat (Xenical; Roche) in African American and Caucasian children and adolescents with obesity-related comorbid conditions.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2014

At a glance

  • Drugs Orlistat (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2013 Primary endpoint 'Body-mass-index' has been met according to results presented at the 95th Annual Meeting of the Endocrine Society.
    • 18 Jun 2013 Results presented at the 95th Annual Meeting of the Endocrine Society.
    • 26 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top